Umbhali: Clyde Lopez
Umhla Wokudalwa: 24 Eyekhala 2021
Hlaziya Umhla: 1 Utshazimpuzi 2025
Anonim
How does Niacin (B3) Work? (+ Pharmacology)
Ividiyo: How does Niacin (B3) Work? (+ Pharmacology)

Umxholo

I-Niacin luhlobo lwevithamini B3. Ifumaneka ekutyeni okufana negwele, inyama, intlanzi, ubisi, amaqanda, imifuno eluhlaza kunye neenkozo. I-Niacin ikwaveliswa emzimbeni ukusuka kwi-tryptophan, efumaneka kukutya okune-protein. Xa ithathwa njengesongezelelo, i-niacin ihlala ifunyenwe ngokudibanisa nezinye iivithamini ze-B.

Musa ukudida i-niacin kunye ne-NADH, niacinamide, inositol nicotinate, IP-6, okanye i-tryptophan. Jonga uluhlu olwahlukileyo lwezi zihloko.

Iifom zokumiselwa ze-niacin zamkelwe yi-US Food and Drug Administration (i-FDA) ye-cholesterol ephezulu kunye nokwandisa amanqanaba ohlobo oluthile lwe-cholesterol elungileyo, eyaziwa ngokuba yi-HDL. Izongezo ze-Niacin kunye neemveliso zogqirha zithathwa ngomlomo ukunqanda ukusilela kwe-vitamin B3 kunye neemeko ezinxulumene noko ezifana ne-pellagra.

Amayeza endalo aVimba weDatha Ukusebenza kwexabiso ngokusekwe kubungqina besayensi ngokwala manqanaba alandelayo: Ukusebenza, ukusebenza ngokukuko, okunokwenzeka ukuba kusebenze, okungenzeka kungasebenzi, kunokwenzeka ukungasebenzi, ukungasebenzi, kunye nobungqina obungonelanga bokulinganisa.

Ukulinganiswa kokusebenza kwe NIACIN zezi zilandelayo:


Kusenokwenzeka ukuba iyasebenza ...

  • Amanqanaba angaqhelekanga echolesterol okanye amafutha egazi (idyslipidemia). Ezinye iimveliso ze-niacin zamkelwe yi-US Food and Drug Administration (FDA) njengeemveliso zonyango zokunyanga amanqanaba angaqhelekanga amafutha egazi. Ezi mveliso ze-niacin zokumiselwa zihlala ziza ngamandla aphezulu angama-500 mg okanye ngaphezulu. Iifom zokuncedisa ukutya kwe-niacin zihlala ziza ngamandla e-250 mg okanye ngaphantsi. Ukusukela ukuba iidosi eziphezulu kakhulu ze-niacin ziyafuneka ekuphuculeni amanqanaba e-cholesterol, isongezelelo sokutya i-niacin ihlala ingafanelekanga. I-Niacin inokudityaniswa nezinye iziyobisi ezinciphisa i-cholesterol xa ukutya kunye nonyango lwamachiza angonelanga. I-Niacin iphucula amanqanaba e-cholesterol, kodwa ayiziphuculi iziphumo zentliziyo kunye nokuhlaselwa sisifo sentliziyo.
  • Isifo esibangelwa kukusilela kwe-niacin (pellagra). I-Niacin yamkelwe yi-U.S. KuLawulo lokuTya kunye noLawulo lweziyobisi (FDA) kolu setyenziso. Nangona kunjalo, i-niacin inokubangela "ukugungxula" (ukuba bomvu, ukurhawuzelela, kunye nokutswina). Ke enye imveliso, ebizwa ngokuba yi-niacinamide, ngamanye amaxesha ikhethwa kuba ayibangeli le mpembelelo yecala.

Inokwenzeka ukuba isebenze ...

  • Amanqanaba angaqhelekanga amafutha egazi kubantu abane-HIV / AIDS. Ukuthatha i-niacin kubonakala kuphucula amanqanaba e-cholesterol kunye namafutha egazi abizwa ngokuba yi-triglycerides kwizigulana ezikule meko.
  • Ukuhlelwa kweempawu ezonyusa umngcipheko wesifo seswekile, isifo sentliziyo, kunye nokubetha (isifo se-metabolic syndrome). Ukuthatha i-niacin kubonakala kukonyusa amanqanaba e-lipoprotein ephezulu (HDL okanye "elungileyo") ye-cholesterol kunye nokunciphisa amanqanaba egazi elibizwa ngokuba yi-triglycerides kubantu abane-metabolic syndrome. Ukuthatha i-niacin kunye nonyango lwe-omega-3 fatty acid kubonakala kusebenza ngcono.

Ayisebenzi ...

  • Isifo sentliziyo. Uphando oluphezulu lubonisa ukuba i-niacin ayikuthinteli ukuhlaselwa yintliziyo okanye ukubetha kubantu abathatha i-niacin ukuthintela okanye ukunyanga isifo sentliziyo. I-Niacin ayiboniswanga ukunciphisa umngcipheko wokufa. I-Niacin akufuneki ithathwe ukunyanga okanye ukuthintela isifo sentliziyo.

Akukho bungqina baneleyo bokulinganisa ukusebenza ...

  • Ukuqina kwemithambo (atherosclerosis). Ukuthatha i-niacin ngomlomo kunye namayeza abizwa ngokuba yi-bile acid sequestrants kunokunciphisa ukuqina kwemithambo emadodeni anale meko. Kubonakala ngathi isebenza kakuhle emadodeni anamanqanaba aphezulu egazi elibizwa ngokuba yi-triglycerides. Kodwa ukuthatha i-niacin akubonakali kunciphisa ukuqina kwemithambo kwizigulana ezinemeko ekuthiwa yipheripheral arterial disease (PAD). Kwakhona, i-niacin ayithinteli izehlo zentliziyo ezinje ngesifo sentliziyo okanye ukubetha.
  • Isifo se-Alzheimer. Abantu abatya izixa eziphezulu ze-niacin ekutyeni nakwiimultivitamini kubonakala ngathi banomngcipheko ophantsi wokufumana isifo se-Alzheimer kunabantu abatya i-niacin encinci. Kodwa abukho ubungqina bokuba ukuthatha isongezelelo se-niacin kuyanceda ukunqanda isifo se-Alzheimer.
  • Iimpawu. Abantu abatya ukutya okuphezulu kwi-niacin banokuba nethuba elincitshisiweyo lokuphuhlisa i-cataract yenyukliya. I-cataract yenyukliya lolona hlobo luqhelekileyo lwe-cataract. Iziphumo zokuthatha i-niacin supplementation azaziwa.
  • Usulelo lwamathumbu olubangela urhudo (ikholera). Ukuthatha i-niacin ngomlomo kubonakala kunciphisa urhudo kubantu abanekholera.
  • Ukungasebenzi kakuhle kwe-Erectile (ED). Ukuthatha i-niacin ekhululwe ixesha elide ngexesha lokulala kwiiveki ze-12 kubonakala ngathi kunceda amadoda ane-ED kunye namanqanaba aphezulu eepid agcina ulwakhiwo ngexesha lokwabelana ngesondo.
  • Amanqanaba aphezulu e-phosphate egazini (hyperphosphatemia). Abantu abanokusilela kwezintso banokuba namanqanaba aphezulu egazi le-phosphate. Olunye uphando lwakwangoko lubonisa ukuba ukuthatha i-niacin kunokunciphisa amanqanaba egazi le-phosphate kubantu abanezifo zezintso zokugqibela kunye namanqanaba aphezulu egazi le-phosphate. Kodwa olunye uphando lubonisa ukuba ukuthatha i-niacin akwehlisi amanqanaba e-phosphate egazini kubantu abathatha amayeza asetyenziselwa ukuthoba amanqanaba e-phosphate egazini.
  • Ukuvaleka kwemithambo esweni (ukuvalwa kwethambo lomthambo): Uphando lwakwangoko lubonisa ukuba ukuthatha i-niacin kunokuphucula ukubona kubantu abanale meko.
  • Isifo seSickle cellUphando lwakwangoko lubonisa ukuba ukuthatha i-niacin akuphuculi amanqanaba e-gazi kubantu abanesifo se-sickle cell.
  • Amabala.
  • Ukusetyenziswa kotywala kotywala.
  • Ukusebenza kwezemidlalo.
  • Ukuqwalaselwa kwentsilelo-yokuchaphazeleka kwengqondo (ADHD).
  • Uxinzelelo.
  • Ukuba nesiyezi.
  • Imibono ebangelwa ziziyobisi.
  • Migraine.
  • Ukugula kwesithuthi.
  • Ischizophrenia.
  • Ezinye iimeko.
Ubungqina obungakumbi buyafuneka ukukala i-niacin kwezi zinto zisetyenziswayo.

I-Niacin ifunxwa ngumzimba xa inyibilika emanzini kwaye ithathwa ngomlomo. Iyaguqulelwa kwi-niacinamide ukuba ithathwe ngezixa ezikhulu kunoko kufunwa ngumzimba.

I-Niacin iyimfuneko ekusebenzeni kakuhle kwamafutha kunye neeswekile emzimbeni kunye nokugcina iiseli ezisempilweni. Kwiidosi eziphezulu, i-niacin inokunceda abantu abanesifo sentliziyo ngenxa yeziphumo zayo ezilungileyo ekunqandeni. Inokuphucula amanqanaba ohlobo oluthile lwamafutha abizwa ngokuba yi-triglycerides egazini.

Ukunqongophala kwe-Niacin kunokubangela imeko ebizwa ngokuba yi-pellagra, ebangela ukucaphuka kolusu, urhudo kunye nesifo sengqondo esixhalabisayo. I-Pellagra yayiqhelekile kwinkulungwane yamashumi amabini, kodwa ayixhaphakanga ngoku, kuba ukutya okunomgubo ngoku kuqiniswe nge-niacin. I-Pellagra isuswe phantse kwinkcubeko yasentshona.

Abantu abanokutya okungalunganga, utywala, kunye nezinye iintlobo zamathumba akhula kancinci abizwa ngokuba zii-carcinoid tumors angaba semngciphekweni wokusilela kwe-niacin. Xa kuthathwa ngomlomo: Niacin ngu NGOKUKHUSELEKILEYO kubantu abaninzi xa bethathwe ngokufanelekileyo. Imveliso yonyango ene-niacin ikhuselekile xa ithathwa njengoko kuyalelwe. Ukutya okune-Niacin okanye izongezo ze-niacin zikhuselekile xa zithathwa ngeedosi ezingaphantsi kwe-35 mcg yonke imihla.

Impembelelo yecala eliqhelekileyo le-niacin yindlela yokuphendula. Oku kunokubangela ukutshisa, ukurhawuzelela, ukurhawuzelela, kunye nobomvu kobuso, iingalo, nesifuba, kunye nentloko. Ukuqala ngeedosi ezincinci ze-niacin kunye nokuthatha i-325 mg ye-aspirin ngaphambi kwethamo ngalinye le-niacin kuya kunceda ukunciphisa ukushukuma okugungxulileyo. Ngokwesiqhelo, le mpendulo iyahamba njengoko umzimba uqhela amayeza. Utywala bunokwenza ukuba impendulo yokugungxula ibe mbi ngakumbi. Gwema izixa ezikhulu zotywala ngelixa uthatha i-niacin.

Ezinye iziphumo ebezingalindelekanga ezincinci ze-niacin kukukhathazeka sisisu, igesi yamathumbu, isiyezi, iintlungu emlonyeni kunye nezinye iingxaki.

Xa kuthathwa iidosi ezingaphezu kwe-3 gram ngosuku lwe-niacin, iziphumo ebezingalindelekanga ezibi kakhulu zinokwenzeka. Oku kubandakanya iingxaki zesibindi, igawuthi, izilonda zendlela yokwetyisa, ukungaboni kakuhle, iswekile ephezulu yegazi, ukubetha kwentliziyo ngendlela engaqhelekanga, kunye nezinye iingxaki ezinzulu.

Amanyathelo okhuseleko kunye nezilumkiso:

Ukukhulelwa kunye nokuncancisa: Niacin ngu NGOKUKHUSELEKILEYO kubafazi abakhulelweyo nabancancisayo xa bethathwe ngomlomo kwixabiso elicetyiswayo. Elona nani liphezulu licetyiswayo le-niacin labafazi abakhulelweyo okanye abancancisayo ngama-30 mg ngosuku ngabafazi abangaphantsi kweminyaka eli-18 ubudala, kunye nama-35 mg kubafazi abangaphezulu kwe-18.

Abantwana: Niacin ngu NGOKUKHUSELEKILEYO xa ithathwa ngomlomo kwixabiso elicetyiswayo kwiqela ngalinye leminyaka. Kodwa abantwana kufuneka bakuphephe ukuthatha idosi ye-niacin ngaphezulu kwemida ephezulu yemihla ngemihla, eyi-10 mg yabantwana abaneminyaka eyi-1-3 ubudala, i-15 mg yabantwana abaneminyaka engama-4-8 ubudala, i-20 mg yabantwana abaneminyaka eli-9-13 ubudala, kunye 30 mg kubantwana abaneminyaka eli-14-18 ubudala.

Umzimba: I-Niacin inokuzenza mandundu i-allergies ngokubangela i-histamine, ikhemikhali enoxanduva lweempawu zokungabikho komzimba, ukuba ikhutshwe.

Isifo sentliziyo / i-angina engazinzangaAmanani amakhulu e-niacin anokunyusa umngcipheko wokubetha kwentliziyo ngokungaqhelekanga. Sebenzisa ngononophelo.

Isifo seCrohnAbantu abanesifo sikaCrohn banokuba namanqanaba asezantsi e-niacin kwaye bafuna ukuxhaswa ngexesha lokuphakama.

Seswekile: I-Niacin inokunyusa iswekile yegazi. Abantu abanesifo seswekile abathatha i-niacin kufuneka bahlole iswekile yegazi labo ngononophelo.

Isifo senyongo: I-Niacin inokusenza mandundu isifo se-gallbladder.

Igawuthi: Inani elikhulu le-niacin linokuzisa igawuthi.

Isifo sezintso: I-Niacin inokuqokelelana kubantu abanesifo sezintso. Oku kunokubangela ingozi.

Isifo sesibindi: I-Niacin inokunyusa ukonakala kwesibindi. Sukusebenzisa izixa ezikhulu ukuba unesifo sesibindi.

Izilonda esiswini okanye emathunjini: I-Niacin inokwenza izilonda zibe mbi ngakumbi. Sukusebenzisa izixa ezikhulu ukuba unezilonda.

Uxinzelelo lwegazi oluphantsi kakhulu: I-Niacin inokunciphisa uxinzelelo lwegazi kwaye iyenze mandundu le meko.

Ugqirha: I-Niacin inokuphazamisana nolawulo lweswekile yegazi ngexesha nasemva kotyando. Yeka ukuthatha i-niacin ubuncinci iiveki ezi-2 ngaphambi kotyando olucwangcisiweyo.

Amanqatha afakwa kwindawo ejikeleze imisipha: I-Niacin inokunyusa umngcipheko wosulelo kwii-xanthomas.

Iingxaki ze-thyroid: I-Thyroxine yincindi yedlala eveliswe yidlala lengqula. I-Niacin inokunciphisa amanqanaba egazi e-thyroxine. Oku kunokuba mandundu ngakumbi kweempawu ezithile zeengxaki ze-thyroid.

Iphakathi
Lumka ngale nhlanganisela.
Utywala (i-Ethanol)
I-Niacin inokubangela ukuba ugungxule kwaye urhawuzelele. Ukusela utywala kunye ne-niacin kunokwenza ukuba ukugungxula kunye nokurhawuzelela kube kubi. Kukho inkxalabo yokuba ukusela utywala kunye ne-niacin kunokunyusa ithuba lokonakaliswa kwesibindi.
IAllopurinol (iZyloprim)
I-Allopurinol (iZyloprim) isetyenziselwa ukunyanga igawuthi. Ukuthatha iidosi ezinkulu ze-niacin kunokubangela ukuba i-gout ibe mandundu kwaye kunciphise ukusebenza kwe-allopurinol (iZyloprim).
IClonidine (iCatapres)
I-Clonidine kunye ne-niacin zombini uxinzelelo lwegazi. Ukuthatha i-niacin kunye ne-clonidine kunokubangela ukuba uxinzelelo lwegazi lube sezantsi kakhulu.
IGemfibrozil (iLopid)
Ukuthatha i-niacin kunye ne-gemfibrozil kunokubangela ukonakala kwemisipha kwabanye abantu. Sebenzisa ngononophelo.
Amayeza eswekile (iziyobisi zeAntidiabetes)
Ukusetyenziswa kweedosi eziphezulu ze-niacin (malunga ne-3-4 yeegram mihla le) kunokunyusa iswekile yegazi. Ngokwandisa iswekile yegazi, i-niacin inokunciphisa ukusebenza kwamayeza eswekile. Jonga eswekile yegazi lakho ngokusondeleyo. Umthamo weyeza lakho leswekile unokufuna ukuba utshintshwe.

Amanye amayeza asetyenziselwa isifo seswekile afaka i-glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), metformin (Glucophage), nateglinide (Starlix), repaglinide (Prandin), chlorpropamide ( Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), kunye nabanye.
Amayeza oxinzelelo lwegazi oluphezulu (iziyobisi ezichasayo)
Ukusebenzisa i-niacin ngamachiza anciphisa uxinzelelo lwegazi kunokunyusa iziphumo zala machiza kwaye kunokunciphisa uxinzelelo lwegazi kakhulu.

Amanye amayeza oxinzelelo lwegazi aphezulu abandakanya i-captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), amlodipine (Norvasc), hydrochlorothiazide (HydroDIURIL), furosemide (Lasix), kunye nabanye abaninzi. .
Amayeza anokwenzakalisa isibindi (iziyobisi zeHepatotoxic)
I-Niacin inokwenzakalisa isibindi. Ukulondolozwa okuzinzileyo kwamalungiselelo e-niacin kubonakala ngathi kukho umngcipheko omkhulu. Ukuthatha i-niacin kunye neyeza elinokwenzakalisa isibindi kunokunyusa umngcipheko wokonakala kwesibindi. Musa ukuthatha i-niacin ukuba uthatha iyeza elinokwenzakalisa isibindi.

Amanye amayeza anokwenzakalisa isibindi abandakanya i-acetaminophen (iTylenol kunye nezinye), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporaconazole) erythromycin (Erythrocin, Ilosone, abanye), phenytoin (Dilantin), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), kunye nabanye abaninzi.
Amayeza acothisa ukujiya kwegazi (iAnticoagulant / iziyobisi zeAntiplatelet)
I-Niacin inokucotha ukujiya kwegazi. Ukuthatha i-niacin kunye namayeza acothisa ukucoca kunokunyusa amathuba okugruzuka nokopha.

Amanye amayeza acothisa ukucoca igazi aquka iasprini, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, indomethacin (Indocin), ticlopidine (Ticlid), warfarin (Coumadin), kunye nezinye.
Amayeza asetyenziselwa ukunciphisa i-cholesterol (i-Bile acid sequestrants)
Amanye amayeza okunciphisa i-cholesterol ebizwa ngokuba yi-bile acid sequestrants inokunciphisa inani le-niacin elifunxwa ngumzimba. Oku kunokunciphisa ukusebenza kwe-niacin. Thatha i-niacin kunye namayeza ubuncinci iiyure ezingama-4-6 ngaphandle.

Amanye ala mayeza asetyenziselwa ukunciphisa i-cholesterol aquka i-cholestyramine (i-Questran) kunye ne-colestipol (i-Colestid).
Amayeza asetyenziselwa ukuthoba i-cholesterol (Statins)
I-Niacin inokuchaphazela kakubi izihlunu. Amanye amayeza asetyenziselwa ukunciphisa i-cholesterol ebizwa ngokuba yi-statins inokuchaphazela nezihlunu. Ukuthatha i-niacin kunye nala mayeza kunokunyusa umngcipheko weengxaki zemisipha.

Amanye ala mayeza asetyenziselwa i-cholesterol ephezulu aquka i-rosuvastatin (Crestor), atorvastatin (Lipitor), lovastatin (Mevacor), pravastatin (Pravachol), fluvastatin (Lescol), kunye ne-simvastatin (iZocor).
Iprobenecid (iBenemid)
Iprrobenecid isetyenziselwa ukunyanga igawuthi. Ukuthatha iidosi ezinkulu ze-niacin kunokwenzakalisa i-gout kunye nokunciphisa ukusebenza kwe-probenecid.
Isulfinpyrazone (iAnturane)
I-Sulfinpyrazone (Anturane) isetyenziselwa ukunyanga igawuthi. Ukuthatha iidosi ezinkulu ze-niacin kunokwenzakalisa i-gout kunye nokunciphisa ukusebenza kwe-sulfinpyrazone (Anturane).
Idlala lengqula
Umzimba ngokwendalo uvelisa iihomoni ze-thyroid. I-Niacin inokunciphisa amanqanaba ehomoni ye-thyroid. Ukuthatha i-niacin kunye neepilisi zehomoni yedlala kunokunciphisa iziphumo kunye neziphumo ebezingalindelekanga zehomoni yedlala lengqula.
Incinci
Jonga olu dibaniso.
I-Aspirin
I-Aspirin ihlala isetyenziswa kunye ne-niacin ukunciphisa ukugungxulwa okubangelwa yi-niacin. Ukuthatha amathamo aphezulu e-aspirin kunokunciphisa ukuba umzimba ukhawuleza kangakanani ukulahla i-niacin. Oku kunokubangela ukuba kubekho i-niacin eninzi emzimbeni kwaye inokukhokelela kwiziphumo ebezingalindelekanga. Nangona kunjalo, iidosi ezisezantsi zeasprini eziqhele ukusetyenziselwa ukuhlamba okunxulumene ne-niacin akubonakali kuyingxaki.
Isicatshulwa seNicotine (Nicoderm)
I-Niacin ngamanye amaxesha inokubangela ukugungxula kunye nesiyezi. Isicatshulwa se-nicotine sinokubangela ukugungxwa kunye nesiyezi. Ukuthatha i-niacin okanye i-niacinamide kunye nokusebenzisa isicatshulwa se-nicotine kunokunyusa ukubakho kokugungxulwa kwaye ube nesiyezi.
I-Beta-carotene
Indibaniselwano ye-niacin kunye neyeza likagqirha simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol elungileyo") kubantu abanesifo sentliziyo kunye namanqanaba asezantsi e-HDL. Nangona kunjalo, ukuthatha i-niacin kunye nokudityaniswa kwee-antioxidants, kubandakanya i-beta-carotene, kubonakala ngathi kuyaphazamisa oku kunyuka kwi-HDL. Ayaziwa nokuba ngaba esi siphumo senzeka kubantu abangenaso isifo sentliziyo.
Chromium
Ukuthatha i-niacin kunye ne-chromium kunye kunokunciphisa iswekile yegazi. Ukuba unesifo seswekile kwaye uthathe ichromium kunye ne-niacin izongezo kunye, jonga iswekile yegazi lakho ukuze uqiniseke ukuba ayibi sezantsi kakhulu.
Iherbs kunye nezongezo ezinokuthi zenzakalise isibindi
I-Niacin, ngakumbi kwiidosi eziphezulu kunokubangela ukonakala kwesibindi. Ukuthatha i-niacin kunye namanye amayeza okanye izongezo ezinokwenzakalisa isibindi kunokunyusa lo mngcipheko. Ezinye zeemveliso zibandakanya i-androstenedione, igqabi le-borage, i-chaparral, i-comfrey, i-dehydroepiandrosterone (i-DHEA), i-germander, i-kava, ioyile ye-pennyroyal, igwele elibomvu, kunye nezinye.
Iherbs kunye nezongezo ezinokunciphisa uxinzelelo lwegazi
I-Niacin inokunciphisa uxinzelelo lwegazi. Ukuthatha i-niacin kunye namanye amayeza kunye nezongezo ezihlisa uxinzelelo lwegazi kunokubangela ukuba uxinzelelo lwegazi luye kakhulu. Amanye amayeza kunye nezongezo ezinokuhlisa uxinzelelo lwegazi zibandakanya i-andrographis, i-casein peptides, uzipho lwekati, coenzyme Q10, L-arginine, lycium, neting nettle, theanine, nabanye.
Iherbs kunye nezongezo ezinokucothisa igazi
I-Niacin inokucotha ukujiya kwegazi. Sebenzisa i-niacin kunye namanye amayeza kunye nokuncedisa okucothisa ukucoca igazi kunokunyusa umngcipheko wokopha kwabanye abantu. Amanye amayeza alolu hlobo abandakanya i-angelica, i-clove, i-danshen, igalikhi, ijinja, iPanax ginseng, kunye nabanye.
Iti yeKombucha
Kukho inkxalabo yokuba iti yekombucha inganciphisa ukufakwa kwe-niacin. Nangona kunjalo, oku kufuneka kufundwe ngakumbi.
Selenium
Indibaniselwano ye-niacin kunye neyeza likagqirha simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol elungileyo") kubantu abanesifo sentliziyo kunye namanqanaba asezantsi e-HDL. Nangona kunjalo, ukuthatha i-niacin kunye nokudityaniswa kwee-antioxidants, kubandakanya i-selenium, kubonakala ngathi kuyaphazamisa oku kunyuka kwi-HDL. Ayaziwa nokuba ngaba esi siphumo senzeka kubantu abangenaso isifo sentliziyo.
Zama
Ezinye i-tryptophan ezivela ekutyeni zinokuguqulwa zibe yi-niacin emzimbeni. Ukuthatha i-niacin kunye ne-tryptophan kunye kunokunyusa amanqanaba kunye neziphumo ebezingalindelekanga ze-niacin.
Vitamin C
Indibaniselwano ye-niacin kunye neyeza likagqirha simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol elungileyo") kubantu abanesifo sentliziyo kunye namanqanaba asezantsi e-HDL. Nangona kunjalo, ukuthatha i-niacin kunye neendibaniselwano ze-antioxidants, kubandakanya i-vitamin C, kubonakala ngathi kuyaphazamisa oku kunyuka kwe-HDL. Ayaziwa nokuba ngaba esi siphumo senzeka kubantu abangenaso isifo sentliziyo.
Vitamin E
Indibaniselwano ye-niacin kunye neyeza likagqirha simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol elungileyo") kubantu abanesifo sentliziyo kunye namanqanaba asezantsi e-HDL. Nangona kunjalo, ukuthatha i-niacin kunye neendibaniselwano ze-antioxidants, kubandakanya i-vitamin E, kubonakala ngathi kuyaphazamisa oku kunyuka kwi-HDL. Ayaziwa nokuba ngaba esi siphumo senzeka kubantu abangenaso isifo sentliziyo.
Izinki
Umzimba unokwenza i-niacin. Abantu abangondlekanga kwaye banesiphene se-niacin, njengotywala obungapheliyo, benza i-niacin eyongezelelweyo ukuba bathatha i-zinc. Kunokubakho umngcipheko owandileyo weziphumo ebezingalindelekanga ezinxulumene ne-niacin njengokugungxula nokurhawuzelela ukuba i-niacin kunye ne-zinc zithathwa kunye.
Iziselo ezishushu
I-Niacin inokubangela ukugungxwa kunye nokurhawuzelela. Ezi ziphumo zinokwandiswa ukuba i-niacin ithathwa ngesiselo esishushu.
La machiza alandelayo afundwe kuphando lwezesayensi:

ABADALA

NGOMLOMO:
  • NgokubanziOlunye uluhlu lweemveliso zokuncedisa ekudleni uluhlu lwe-niacin kwileyibhile kwi-niacin equivalents (NE). 1 mg ye-niacin iyafana ne-1 mg NE. Xa i-niacin idweliswe kwileyibhile njenge-NE, inokubandakanya ezinye iindlela ze-niacin ngokunjalo, kubandakanya i-niacinamide, inositol nicotinate, kunye ne-tryptophan. Izibonelelo zokutya ezicetyiswayo mihla le (ii-RDAs) ze-niacin kubantu abadala zi-16 mg NE zamadoda, i-14 mg NE yabasetyhini, i-18 mg NE yabasetyhini abakhulelweyo, kunye ne-17 mg NE yabafazi abancancisayo.
  • Kuba cholesterol ephezulu: Iziphumo ze-niacin zixhomekeke kwidosi. Amanani e-niacin asezantsi njenge-50 mg kwaye aphezulu njenge-12 yeegram suku ngalunye asetyenzisiweyo. Nangona kunjalo, ukonyuka okukhulu kwi-HDL kunye nokuhla kwe-triglycerides kwenzeka nge-1200 ukuya kwi-1500 mg / ngosuku. Iziphumo ezinkulu ze-Niacin kwi-LDL zenzeka ngo-2000 ukuya ku-3000 mg / ngosuku. I-Niacin ihlala isetyenziswa namanye amayeza okuphucula amanqanaba e-cholesterol.
  • Ukuthintela nokunyanga ukusilela kwe-vitamin B3 kunye neemeko ezinxulumene noko ezifana nepellagra: 300-1000 mg yonke imihla ngeedosi ezahluliweyo.
  • Ukunyanga ukuqina kwemithambo: Iidosi ze-niacin ziye zaphakama njenge-12 yeigram mihla le. Nangona kunjalo, idosi emalunga ne-1 ukuya kwi-4 yeigram ye-niacin yonke imihla, iyodwa okanye kunye ne-statins okanye i-bile acid sequestrants (iyeza elinciphisa i-cholesterol), sele isetyenzisiwe ukuya kuthi ga kwiminyaka eyi-6.2.
  • Ukunciphisa ukulahleka kolwelo okubangelwa yityhefu yekholeraKusetyenziswe iigrama ezi-2 yonke imihla.
  • Kwinqanaba lamafutha egazi ngokungaqhelekanga ngenxa yonyango lwe-HIV / AIDSKusetyenziswe iigrama ezi-2 yonke imihla.
  • Isifo se-metabolic syndromeI-2 gram ye-niacin ithathwe yonke imihla iiveki ezili-16. Ngamanye amaxesha, i-niacin 2 gram yonke imihla, iyodwa okanye kule dosi, ithathwa kunye ne-4 gram ye-omega-3 ethyl esters (Lovaza, GlaxoSmithKline Pharmaceuticals).
NGU-IV:
  • Ukuthintela nokunyanga ukusilela kwe-vitamin B3 kunye neemeko ezinxulumene noko ezifana nepellagraI-60 mg ye-niacin isetyenzisiwe.
NJENGOKO
  • Ukuthintela nokunyanga ukusilela kwe-vitamin B3 kunye neemeko ezinxulumene noko ezifana nepellagraI-60 mg ye-niacin isetyenzisiwe.
ABANTWANA

NGOMLOMO:
  • NgokubanziIzibonelelo zokutya ezicetyiswayo zemihla ngemihla (ii-RDAs) ze-niacin ebantwaneni zii-2 mg NE kwiintsana ezinenyanga ezi-0-6, i-4 mg NE yabantwana kwiinyanga eziyi-7-12 ubudala, i-6 mg NE yabantwana abaneminyaka eyi-1-3, I-8 mg NE yabantwana abaneminyaka engama-4-8 ubudala, i-12 mg NE yabantwana abaneminyaka engama-9-13 ubudala, i-16 mg NE yabafana abaneminyaka eyi-14-18 ubudala, kunye ne-14 mg NE yamantombazana aneminyaka eli-14-18 ubudala.
  • Ukuthintela nokunyanga ukusilela kwe-vitamin B3 kunye neemeko ezinxulumene noko ezifana nepellagra: 100-300 mg ngosuku lwe-niacin, enikwe ngeedosi ezahluliweyo.
3-Pyridinecarboxylic Acid, Acide Nicotinique, Acide Pyridine-Carboxylique-3, Anti-Blacktongue Factor, Antipellagra Factor, B Complex Vitamin, Complexe de Vitamines B, Facteur Anti-Pellagre, Niacina, Niacine, Nicosedine, Nicotinic Aciding, Nicotinic Aciding, Vitamin B3, Vitamin PP, Vitamina B3, Vitamine B3, Vitamine PP.

Ukuze ufunde okungakumbi malunga nokubhalwa kweli nqaku, nceda ubone Amayeza endalo aVimba weDatha indlela yokusebenza.


  1. UAnderson TJ, uGrégoire J, uPearson GJ, et al. Izikhokelo zoMbutho weCardiovascular Society ka-2016 woLawulo lweDyslipidemia yoThintelo lweZifo zeCardiovascular in the Adult. Ngaba uJ Cardiol. Ngo-2016; 32: 1263-1282. Jonga i-abstract.
  2. Ilitye NJ, uRobinson JG, uLichtenstein AH, et al. Isikhokelo se-ACC / AHA sango-2013 kunyango lwecholesterol yegazi ukunciphisa umngcipheko wentliziyo kubantu abadala: ingxelo yeAmerican College of Cardiology / American Heart Association. NdinguColl Cardiol 2014; 63: 2889-934. Jonga i-abstract.
  3. ILloyd-Jones DM, iMorris PB, iBallantyne CM, et al. Isigqibo sesivumelwano se-ACC se-ACC malunga nendima yezonyango ezingezizo ezesistim ze-LDL-cholesterol ekunciphiseni kulawulo lwe-atherosclerotic cardiovascular disease risk: ingxelo yeAmerican College of Cardiology task Force kumaxwebhu ekliniki yokuvumelana. J NdinguColl weCardiol 2016; 68: 92-125. Jonga i-abstract.
  4. UMontserrat-de la Paz S, uLopez S, uBermudez B, et al. Iziphumo zokukhululwa kwangoko kwe-niacin kunye nokutya okunamafutha e-acid kwi-insulin ebukhali kunye nenqanaba le-lipid kubantu abane-metabolic syndrome. J Sci Ukutya kweZolimo 2018; 98: 2194-200. Jonga i-abstract.
  5. UJenkins DJA, Spence JD, Giovannucci EL, okqhubekayo. Iivithamini ezongezelelekileyo kunye neeminerali kuthintelo kunye nonyango lweCVD. NdinguColl Cardiol 2018; 71: 2570-84. Jonga i-abstract.
  6. USahebkar A, uReiner Z, uSimental-Mendia LE, uFerretti G, uCicero AF. Iziphumo zokukhutshwa kwe-niacin eyandisiweyo kwiplasma lipoprotein (a) kumanqanaba: Ukuphononongwa ngokuchanekileyo kunye nohlalutyo lweemeta zezilingo ezilawulwa ngokungenamthetho. Imetabolism. NgoNovemba ka-2016; 65: 1664-78. Jonga i-abstract.
  7. UGaynon MW, uPaulus YM, uRahimy E, uAlexander JL, uMansour SE. Iziphumo ze-niacin yomlomo kwi-central retinal vein occlusion. Amangcwaba eArch Clin kwi-Ophthalmol. Ngo-2017 uJuni; 255: 1085-92. Jonga i-abstract.
  8. Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. I-Niacin yothintelo lokuqala kunye nolwesibini lweziganeko zentliziyo. Isiseko sedatha yeCochrane Isityhi 2017 Jun 14; 6: CD009744. Jonga i-abstract.
  9. ILin C, Grandinetti A, Shikuma C, et al. Iziphumo zokukhutshwa kwe-niacin eyandisiweyo kwi-lipoprotein sub-particle concentrations kwizigulana ezine-HIV. IHawaii J Med yezeMpilo yoLuntu. Ngo-2013 ngoMatshi; 72: 123-7. Jonga i-abstract.
  10. I-Scoffone HM, iKrajewski M, iZorca S, et al. Ukhuseleko Iziphumo zokukhutshwa kwe-niacin eyandisiweyo kwi-serum lipids kunye nasekusebenzeni kwe-endothelial kubantu abadala abane-sickle cell anemia kunye ne-high-density lipoprotein cholesterol. NdinguJ Cardiol. Ngo-2013 uNov 1; 112: 1499-504. Jonga i-abstract.
  11. UBrunner G, uYang EY, uKumar A, et al. Iziphumo zokuguqulwa kwe-lipid kwisifo se-arteripheral isifo emva kwetyala lokungenelela kwe-endovascular (ELIMIT). I-atherosclerosis. NgoDisemba wama-2013; 213: 371-7. Jonga i-abstract.
  12. UGoldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Unyango lwe-Niacin kunye nomngcipheko wesifo seswekile esitsha: uhlalutyo lweemeta zezilingo ezilawulwa ngokungahleliwe. Intliziyo. NgoFebruwari 2016; 102: 198-203. Jonga i-abstract.
  13. Uxwebhu lweenkcukacha ze-PL, iNdima yeeNgcaciso zeDyslipidemia. Ileta ka-Pharmacist / Ileta yoMmeli. Isilimela 2016; 32: 320601.
  14. Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE; AIM-HIGH Abaphandi. Unyango lwe-niacin olwandisiweyo kunye nomngcipheko we-ischemic stroke kwizigulana ezinesifo sentliziyo: Ungenelelo lwe-Atherothrombosis kwi-Metabolic Syndrome ene-HDL / High Triglycerides: Impembelelo kwiziphumo zezeMpilo zeHlabathi (AIM-HIGH). Ukubetha. Ngo-2013 Oktobha; 44: 2688-93. Jonga i-abstract.
  15. Umchebi GC, uPottala JV, uHansen SN, uBrandenburg V, uHarris WS. Iziphumo zokumiselwa kwe-niacin kunye ne-omega-3 fatty acids kwi-lipids kunye nomsebenzi we-vascular kwi-metabolic syndrome: ityala elilawulwa ngokungahleliwe. J Lipid Res. Ngo-2012 uNov; 53: 2429-35. Jonga i-abstract.
  16. I-Sazonov V, iMaccubbin D, iSisk CM, iCanner PL. Iziphumo ze-niacin kwizigulo zesifo seswekile esitsha kunye neziganeko zentliziyo kwizigulana ezine-normoglycaemia kunye ne-glucose yokuzila engalunganga. Int J Clin Ukuziqhelanisa. Ngo-2013 ngoMatshi; 67: 297-302. Jonga i-abstract.
  17. IPhilpott AC, iHubacek J, iLanga YC, uHillard D, kunye noAnderson TJ. I-Niacin iphucula iprofayili ye-lipid kodwa hayi ukusebenza kwe-endothelial kwizigulana ezinesifo semithambo ye-coronary kwi-dose ephezulu yonyango lwe-statin. I-atherosclerosis. NgoFebruwari 2013; 226: 453-8. Jonga i-abstract.
  18. U-Loebl T, Raskin S. Ingxelo yenkundla yenqaku: isigulo esibuhlungu se-manic psychotic emva konyango nge-niacin. J Neuropsychiatry Iklinikhi yeNeurosci. Ukuwa kuka-2013; 25: E14. Jonga i-abstract.
  19. Inkulumbuso yaseLavigne, Karas RH. Imeko yangoku ye-niacin kuthintelo lwezifo zentliziyo: uphononongo olucwangcisiweyo kunye nokuhlengahlengiswa kwemeta. J NdinguColl Cardiol. Ngo-2013 uJan 29; 61: 440-6. Jonga i-abstract.
  20. ILakey WC, iGreyshock N, iGuyton JR. Ukuphendula okungalunganga kwe-Achilles tendon xanthomas kwizigulana ezintathu ze-hypercholesterolemic emva kokuqiniswa konyango kunye ne-niacin kunye ne-bile acid sequestrants. J Ikliniki yeLipidol. Ngo-2013 ngoMatshi-Epreli; 7: 178-81. Jonga i-abstract.
  21. Kei A, Liberopoulos EN, Mikhailidis DP, Elisaf M. Thelekisa ukutshintshela kwelona thamo liphezulu le-rosuvastatin vs ukongeza i-nicotinic acid ngokuchasene nefenofibrate yokuxuba i-dyslipidaemia. Int J Clin Ukuziqhelanisa. Ngo-2013 ngoMeyi; 67: 412-9. Jonga i-abstract.
  22. UKeene D, Ixabiso C, uShun-Shin MJ, uFrancis DP. Iziphumo kumngcipheko weentliziyo kunye noxinzelelo oluphezulu lweepoprotein ekujolise kuzo kunyango lwe-niacin, i-fibrate, kunye ne-CETP inhibitors: uhlalutyo lweemeta zezilingo ezilawulwa ngokungahleliwe kubandakanya nezigulana ezili-117,411. BMJ. Ngo-2014 uJulayi 18; 349: g4379. Jonga i-abstract.
  23. Yena YM, Feng L, Huo DM, Yang ZH, Liao YH. Izibonelelo kunye nokwenzakala kwe-niacin kunye ne-analog yayo kwizigulana zedialysis ye-renal: uphononongo olucwangcisiweyo kunye nohlalutyo lweemeta. Int Urol Nephrol. NgoFebruwari 2014; 46: 433-42. Jonga i-abstract.
  24. UGuyton JR, uFazio S, uAdewale AJ, uJensen E, uTomassini JE, u-Shah A, uTershakovec AM. Iziphumo zokukhutshwa kwe-niacin eyandisiweyo kwisifo seswekile esitsha phakathi kwabaguli abanyangwa nge-ezetimibe / simvastatin kuvavanyo olulawulwa ngononophelo. Unonophelo lweSwekile. Ngo-2012 kuMatshi; 35: 857-60. Jonga i-abstract.
  25. UDavidson MH, uRooney M, uPollock E, uDrucker J, uChoy Y. Iziphumo ze-colesevelam kunye ne-niacin kwi-low-density lipoprotein cholesterol kunye nolawulo lwe-glycemic kwizifundo ezine-dyslipidemia kunye ne-glucose yokuzila engalunganga. J Ikliniki yeLipidol. Ngo-2013 Sep-Okthobha; 7: 423-32. Jonga i-abstract.
  26. I-Bassan M. Ityala lokukhutshwa kwangoko kwe-niacin. Imiphunga Yentliziyo. Ngo-2012 uJan-Feb; 41: 95-8. Jonga i-abstract.
  27. I-Aramwit P, i-Srisawadwong R, i-Supasyndh O. Ukusebenza kunye nokukhuseleka kwe-nicotinic acid eyandisiweyo yokunciphisa i-serum phosphorus kwizigulana ze-hemodialysis. J Nephrol. Ngo-2012 ngoMeyi-ngoJuni; 25: 354-62. Jonga i-abstract.
  28. U-Ali EH, McJunkin B, Jubelirer S, Hood W. Niacin wenza ukuba i-coagulopathy ibonakalise ukulimala kwesibindi. W V Med J. 2013 Jan-Feb; 109: 12-4 Jonga i-abstract.
  29. Urberg, M., Benyi, J., noJohn, R. Iziphumo zehypocholesterolemic ye-nicotinic acid kunye ne-chromium supplementation. J Fam Ukukhetha. Ngo-1988; 27: 603-606. Jonga i-abstract.
  30. Hendrix, CR, Housh, TJ, Mielke, M., Zuniga, JM, Camic, CL, Johnson, GO, Schmidt, RJ, kunye neHoush, i-DJ Iziphumo ezibi kakhulu zesongezelelo se-caffeine esinebhentshi yokucinezela kunye namandla omlenze wolwandiso kunye nexesha ukudinwa ngexesha lomjikelo we-ergometry. J Amandla.Cond. Res 2010; 24: 859-865. Jonga i-abstract.
  31. Ikhiwane HL, Ikhiwane J, uSouney PF, et al. Thelekisa ukukhutshwa kwe-nicotinuric acid emva kokungenisa kwamalungiselelo amabini e-nicotinic acid kulungiselelo lomntu. J eKliniki kwi-Pharmacol. Ngo-1988 uDec; 28: 1136-40. Jonga i-abstract.
  32. UMrochek JE, uJolley RL, iDS encinci, uTurner WJ. Impendulo yeMetabolic yabantu ekungeniseni i-nicotinic acid kunye ne-nicotinamide. KwiKlinikhi Chem. Ngo-1976; 22: 1821-7. Jonga i-abstract.
  33. I-Neuvonen PJ, i-Roivas L, i-Laine K, i-Sundholm O. Ukufumaneka kokukhutshelwa okuzinzileyo kwe-nicotinic acid formulations. UBr J Clin Pharmacol. Ngo-1991; 32: 473-6. Jonga i-abstract.
  34. UMonon RM, uAdams MH, uGonzález MA, uTolbert DS, uLeu JH, uCefali EA. I-Plasma kunye nomchamo we-pharmacokinetics ye-niacin kunye nemetabolites yayo kulwandiso lwe-niacin eyandisiweyo. I-Int J kwikliniki ye-Pharmacol Ther. Ngo-2007; 45: 448-54. Jonga i-abstract.
  35. UKarpe F, uFrayn KN. I-nicotinic acid receptor-yindlela entsha yesiyobisi esidala. ILancet. Ngo-2004; 363: 1892-4. Jonga i-abstract.
  36. Amatyala S, Smith SJ, Zheng YW, et al. Ukuchongwa kohlobo lofaka ikhowudi kwi-acyl CoA: diacylglycerol acyltransferase, isitshixo se-enzyme kwi-triacylglycerol synthesis. Inkqubo yeNatl Acad Sci U S A. 1998; 95: 13018-23. Jonga i-abstract.
  37. IGanji SH, iTavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. I-Niacin ngokungakhuphisaniyo inqanda i-DGAT2 kodwa hayi umsebenzi we-DGAT1 kwiiseli ze-HepG2. J Lipid Res. Ngo-2004; 45: 1835-45. Jonga i-abstract.
  38. Tornvall P, Hamsten A, Johansson J, Carlson LA. Ukuqheleka kobume be-lipoprotein ephantsi kakhulu kwi-hypertriglyceridemia yi-nicotinic acid. I-atherosclerosis. Ngo-1990; 84 (2-3): 219-27. Jonga i-abstract.
  39. UMorgan JM, uCapuzzi DM, uBaksh RI, et al. Iziphumo zokukhutshwa kwe-niacin eyandisiweyo kusasazo lwe-lipoprotein subclass. NdinguJ Cardiol. 2003; 91: 1432-6. Jonga i-abstract.
  40. UJin FY, uKamanna VS, uKashyap ML. I-Niacin inciphisa ukususwa kwe-lipoprotein apolipoprotein A-I kodwa hayi i-cholesterol ester ngeeseli zeHep G2. Impembelelo yokuthuthwa ngokutsha kwe-cholesterol. IArterioscler Thromb Vasc Biol. Ngo-1997; 17: 2020-8. Jonga i-abstract.
  41. UVincent JE, uZijlstra FJ. I-Nicotinic acid inhibit synthesis ye-thromboxane kwiiplatelets. Iprostaglandins. Ngo-1978; 15: 629-36. Jonga i-abstract.
  42. UDatta S, Das DK, Engelman RM, et al. Ukuphuculwa kolondolozo lwe-myocardial yi-nicotinic acid, ikhompawundi ye-antilipolytic: indlela yokusebenza. Isiseko seKhadi Cardiol. Ngo-1989; 84: 63-76. Jonga i-abstract.
  43. Turjman N, Cardamone A, Gotterer GS kunye noHendrix TR. Iziphumo ze-nicotinic acid kwi-cholera-indased fluid yokuhamba kunye nokungasebenzi kwe-sodium fluxes kwi-rabbit jejunum. UJohn Hopkins Med J. 1980; 147: 209-11. Jonga i-abstract.
  44. Unna K. Izifundo ngobutyhefu kunye nakumachiza e-nicotinic acid. UJ Pharmacol Exp Ther 1939; 65: 95-103.
  45. IBrazda FG kunye neCoulson RA. Ubutyhefu be-nicotinic acid kunye nezinye ezivela kuzo. Iproc Soc Exp Biol Med 1946; 62: 19-20.
  46. U-Chen KK, uRose CL, uRobbins EB. Ubungozi be-nicotinic acid. Iprok Soc Exp Biol Med 1938; 38: 241-245.
  47. UFraunfelder FW, uFraunfelder FT, Illingworth DR. Iziphumo ezichaseneyo zeoyile ezinxulunyaniswa nonyango lwe-niacin. UBr J Ophthalmol. 1995; 79: 54-56.
  48. I-Litin SC, kunye no-Anderson CF. I-myopathy ehambelana neNicotinic acid: ingxelo yamatyala amathathu. NdinguJ Med. 1989; 86: 481-3.
  49. UGharavi AG, iDayimane JA, uSmith DA, uPhillips RA. I-myopathy ebangelwa yi-Niacin. NdinguJ Cardiol. Ngo-1994; 74: 841-2. Jonga i-abstract.
  50. O'REILLY PO, CALLBECK MJ, HOFFER A. Ukukhutshwa okuzinzileyo kwe-nicotinic acid (nicospan); Iziphumo kumanqanaba e-cholesterol kunye nee-leukocyte. Ngaba uMed Assoc J. 1959; 80: 359-62. Jonga i-abstract.
  51. Umhlaba TP, Odom L, Mullins CA. I-Lactic acidosis enxulunyaniswa nonyango lwe-niacin yedosi ephezulu. UMzantsi Med J. 1991; 84: 496-7. Jonga i-abstract.
  52. I-WV emdaka. I-Niacin yokuphazamiseka kwe lipid. Iimpawu, ukusebenza kakuhle, kunye nokhuseleko. Ipostgrad Med. Ngo-1995 uAg; 98: 185-9, 192-3. Jonga i-abstract.
  53. I-Windler E, iZyriax BC, iBamberger C, iRinninger F, iBeil FU. Iindlela zangoku kunye nenkqubela phambili kunyango lwe-hypercholesterolemia. I-Atheroscler Suppl. Ngo-2009; 10: 1-4. Jonga i-abstract.
  54. UKaijser L, u-Eklund B, u-Olsson AG, uCarlson LA. Ukwahlulwa kweziphumo ze-nicotinic acid kwi-vasodilatation kunye ne-lipolysis yi-prostaglandin synthesis inhibitor, indomethacin, emntwini. IMed Biol. Ngo-1979; 57: 114-7. Jonga i-abstract.
  55. I-Eklund B, Kaijser L, Nowak J, Wennmalm A.Iprostaglandins inegalelo kwi-vasodilation ebangelwa yi-nicotinic acid. Iprostaglandins. Ngo-1979; 17: 821-30. Jonga i-abstract.
  56. UAndersson RG, uAberg G, uBrattsand R, uNokia E, uLundholm L. Izifundo malunga nendlela yokugungxula okubangelwa yi-nicotinic acid. I-Acta Pharmacol Toxicol (iCopenh). Ngo-1977 kaJulayi; 41: 1-10. Jonga i-abstract.
  57. UMorgan JM, uCapuzzi DM, uGuyton JR, et al. Unyango lweNiaspan, iNiacin ekhutshwayo elawulwayo, kwizigulana ezineHypercholesterolemia: Uvavanyo olulawulwa yiPlacebo. J Cardiovasc Pharmacol Ther. Ngo-1996; 1: 195-202. Jonga i-abstract.
  58. UAronov DM, uKeenan JM, uAkhmedzhanov NM, et al. Uvavanyo lwezonyango lwe-wax-matrix eqhubekayo yokukhululwa kwe-niacin kwindawo yaseRussia ene-hypercholesterolemia. IArch Fam Med. Ngo-1996; 5: 567-75. Jonga i-abstract.
  59. IGoldberg A, iAlagona P Jr, iCapuzzi DM, et al. Ukusebenza kwethamo elininzi kunye nokukhuseleka kwefom ekhutshiweyo ye-niacin kulawulo lwe-hyperlipidemia. NdinguJ Cardiol. Ngo-2000; 85: 1100-5. Jonga i-abstract.
  60. USmith DT, uRuffin JM, kunye noSmith SG. I-Pellagra iphathwe ngempumelelo nge-nicotinic acid: ingxelo yetyala. IJAMA 1937; 109: 2054-2055.
  61. UFouts PJ, Helmer OM, Lepkovsky S, kunye et al. Unyango lwepellagra yomntu nge-nicotinic acid. Iproc Soc Exp Biol Med 1937; 37: 405-407.
  62. UBrown BG, uBardsley J, uPoulin D, et al. Umthamo ophakathi, unyango lwamachiza amathathu kunye ne-niacin, i-lovastatin, kunye ne-colestipol ukunciphisa i-lipoprotein cholesterol engaphantsi kwe-100 mg / dl kwizigulana ezine-hyperlipidemia kunye ne-coronary artery disease. NdinguJ Cardiol. Ngo-1997; 80: 111-5. Jonga i-abstract.
  63. Ban Ban. Izifundo zengqondo kwezemfundo kunye nomzi mveliso wamayeza. Prog Neuropsychopharmacol Biol Psychiatry. Ngo-2006 ngoMeyi; 30: 429-41.
  64. Lanska DJ. Isahluko 30: Imbali yezinto eziphambili zengxaki yokunqongophala kweevithamini: iivithamini ezinyibilikayo emanzini. Ikliniki ye-Handb Neurol. Ngo-2010; 95: 445-76. Jonga i-abstract.
  65. Berge KG, Canner PL. Iprojekthi yeziyobisi zeCoronary: amava e-niacin. Iqela leCoronary Project Research Group. I-Eur J Clin Pharmacol. Ngo-1991; 40 iSuppl 1: S49-51. Jonga i-abstract.
  66. Akukho babhali badwelisiweyo. Clofibrate kunye ne-niacin kwisifo sentliziyo. JAMA. Ngo-1975 uJan 27; 231: 360-81. Jonga i-abstract.
  67. UHenkin Y, Oberman A, uHurst DC, uSegrest JP. I-Niacin iphinda yaqwalaselwa: ukujongwa kweklinikhi kwichiza elibalulekileyo kodwa elingasetyenziswanga kakuhle. NdinguJ Med. Ngo-1991; 91: 239-46. Jonga i-abstract.
  68. UHenkin Y, Johnson KC, Segrest JP. Rechallenge kunye ne-crystalline niacin emva kwesifo se-hepatitis esibangelwa sisiyobisi kwi-niacin ekhutshiweyo. JAMA. Ngo-1990; 264: 241-3. Jonga i-abstract.
  69. I-Etchason JA, iMiller TD, iiSquires RW, et al. I-Niacin-indened hepatitis: isiphumo esichaphazelekayo esinokukhutshwa ngexesha lokukhutshwa kwe-niacin. Ikliniki ye-Mayo. Ngo-1991; 66: 23-8. Jonga i-abstract.
  70. UShakir KM, uKoll S, u-Aprill BS, uDrake AJ 3, uEisold JF. I-Nicotinic acid inciphisa amanqanaba e-serum ye-thyroid ngelixa igcina imeko ye-euthyroid. Ikliniki yaseMayo. Ngo-1995; 70: 556-8. Jonga i-abstract.
  71. Ugqirha PJ. Utshintsho kwi-thyroid kunye novavanyo lomsebenzi we-hepatic olunxulumene nokulungiswa kwe-niacin ekhutshiweyo. Ikliniki yaseMayo. Ngo-1992; 67: 1206. Jonga i-abstract.
  72. UCashin-Hemphill L, uSpencer CA, uNicoloff JT, et al. Utshintsho kwi-serum thyroid indices indices nge-colestipol-niacin yonyango. UAnn Intern Med. Ngowe-1987; 107: 324-9. Jonga i-abstract.
  73. UDunn RT, iFord MA, iRindone JP, i-Kwiecinski FA. I-Aspirin ye-Low-Dose kunye ne-Ibuprofen yokuNciphisa ukuSabela okuThatywayo okulandela uLawulo lweNiacin. NdinguJ Ther. Ngo-1995; 2: 478-480. Jonga i-abstract.
  74. I-Litin SC, kunye no-Anderson CF. I-nicotinic acid ehambelana ne-myopathy: ingxelo yamatyala amathathu. NdinguJ Med. Ngo-1989; 86: 481-3. Jonga i-abstract.
  75. I-Hexeberg S, i-Retterstøl K. [Hypertriglyceridemia-diagnostics, risk and treatment]. I-Tidsskr kunye neLaegeforen. Ngo-2004; 124: 2746-9. Jonga i-abstract.
  76. UGarnett WR. Ukudibana nehydroxymethylglutaryl-coenzyme A reductase inhibitors. NdinguJ J Syst Pharm. Ngo-1995; 52: 1639-45. Jonga i-abstract.
  77. IGadegbeku CA, iDhandayuthapani A, uShrayyef MZ, uEgan BM. Iziphumo zeHemodynamic ze-nicotinic acid infusion kwizifundo eziqhelekileyo kunye nezixinzelelo. NdinguJ Hypertens. Ngo-2003; 16: 67-71. Jonga i-abstract.
  78. O'Brien T, iSilverberg JD, iNguyen TT. Inicotinic acid-indenedityity inxulunyaniswa necytopenia kunye nokwehla kwamanqanaba e-globulin ebopha i-thyroxine. Ikliniki yaseMayo. Ngo-1992; 67: 465-8. Jonga i-abstract.
  79. Ukujonga i-BD, uLavie CJ, uLohmann TP, uGenton E.I-Niacin-indased factor factor clotting defence kunye ne-coagulopathy. IArch Intern Med. Ngo-1992; 152: 861-3. Jonga i-abstract.
  80. USampathkumar K, uSelvam M, uSooraj YS, uGowthaman S, uAjeshkumar RN. Ukukhululwa kwe-nicotinic acid-iarhente yomlomo yenoveli yolawulo lwephosphate. Int Urol Nephrol. Ngo-2006; 38: 171-4. Jonga i-abstract.
  81. Ng CF, uLee CP, uHo AL, uLee VW. Iziphumo ze-niacin ekusebenzeni kwe-erectile kumadoda ane-erectile dysfunction kunye ne-dyslipidemia. J Ukwabelana ngesondo. Ngo-2011; 8: 2883-93. Jonga i-abstract.
  82. UDuggal JK, uSingh M, uAttri N, et al. Iziphumo zonyango lwe-niacin kwiziphumo zentliziyo kwizigulana ezinesifo semithambo. J Cardiovasc Pharmacol Ther. Ngo-2010; 15: 158-66. Jonga i-abstract.
  83. UCarlson LA, uRosenhamer G. Ukunciphisa ukubhubha eStockholm Ischemic Heart Disease Secondary Study Study ngonyango oludibeneyo kunye ne-clofibrate kunye ne-nicotinic acid. Acta Med Scand. Ngo-1988; 223: 405-18. Jonga i-abstract.
  84. IBlankenhorn DH, uNessim SA, uJohnson RL, et al. Iziphumo ezincedisayo zonyango oluhlangeneyo lwe-colestipol-niacin kwi-coronary atherosclerosis kunye ne-coronary venous bypass graft. JAMA. Ngowe-1987; 257: 3233-40. Jonga i-abstract.
  85. UMack WJ, uSelzer RH, uHodis HN, et al. Unciphiso lonyaka omnye kunye nohlalutyo olude lwe-carotid intima-media thickness ehambelana nonyango lwe-colestipol / niacin. Ukubetha. Ngo-1993; 24: 1779-83. Jonga i-abstract.
  86. IBlankenhorn DH, uSelzer RH, uCrawford DW, okqhubekayo. Iziphumo eziluncedo zonyango lwe-colestipol-niacin kumthambo oqhelekileyo we-carotid. Ukucuthwa kweminyaka emibini kunye nemine yokuqina kwe-intima-media kulinganiswa nge-ultrasound. Ukujikeleza. Ngo-1993; 88: 20-8. Jonga i-abstract.
  87. UBrown BG, uZambon A, uPoulin D, et al. Ukusetyenziswa kwe-niacin, i-statins, kunye ne-resins kwizigulana ezine-hyperlipidemia. NdinguJ Cardiol. Ngo-1998; 81 (4A): 52B-59B. Jonga i-abstract.
  88. UBrown G, uAlbers JJ, uFisher LD, et al. Ukunyanzeliswa kwesifo se-coronary artery njengesiphumo sonyango oluncitshisayo lwe-lipid emadodeni anamanqanaba aphezulu e-apolipoprotein B. N Engl J Med. Ngo-1990; 323: 1289-98. Jonga i-abstract.
  89. UBruckert E, uLabreuche J, uAmarenco P.Uhlalutyo lweemeta zesiphumo se-nicotinic acid yodwa okanye ngokudibeneyo kwimicimbi yentliziyo kunye ne-atherosclerosis. I-atherosclerosis. Ngo-2010; 210: 353-61. Jonga i-abstract.
  90. Iintlola TD, Grant JM, Stone RE, et al. Ukuqwalaselwa kwamva nje kunyango lweepellagrins ezingamakhulu amathandathu kugxininiso olukhethekileyo ekusetyenzisweni kwe-nicotinic acid kwiprophylaxis. UMzantsi Med J 1938; 31: 1231.
  91. IMalfait P, uMoren A, uDillon JC, et al. Ukuqhambuka kwepellagra okunxulumene notshintsho kwi-niacin yokutya phakathi kweembacu zaseMozambiki eMalawi. Int J Epidemiol. Ngo-1993; 22: 504-11. Jonga i-abstract.
  92. UGerber MT, uMondy KE, uYarasheski KE, et al. I-Niacin kubantu abosuleleke yi-HIV abane-hyperlipidemia abafumana unyango olunamandla lwe-antiretroviral. KwiKlinikhi yosulelo lweDis. Ngo-2004; 39: 419-25. Jonga i-abstract.
  93. ILungu lePalamente laseDubé, uWu JW, uAberg JA, et al. Ukhuseleko kunye nokusebenza kokukhutshwa kwe-niacin eyandisiweyo kunyango lwe-dyslipidaemia kwizigulana ezine-HIV: i-AIDS Clinical Trials Group Study A5148. Antivir Ther. Ngo-2006; 11: 1081-9. Jonga i-abstract.
  94. UBalasubramanyam A, uCoraza I, uSmith EO, et al. Umdibaniso we-niacin kunye ne-fenofibrate notshintsho kwindlela yokuphila iphucula i-dyslipidemia kunye ne-hypoadiponectinemia kwizigulana ze-HIV kunyango lwe-antiretroviral: iziphumo "zentliziyo entle," ulingo olulawulwa ngokungenamkhethe. J Ikliniki ye-Endocrinol Metab. Ngo-2011; 96: 2236-47. Jonga i-abstract.
  95. I-Elam MB, iHunninghake DB, iDavis KB, et al. Iziphumo ze-niacin kumanqanaba e-lipid kunye ne-lipoprotein kunye nolawulo lwe-glycemic kwizigulana ezinesifo seswekile kunye nesifo sephepha lomzimba: isifundo se-ADMIT: Uvavanyo olungenamsebenzi. Isifo seNtsholongwane esiTyala lokuNgenelela okuninzi. JAMA. Ngo-2000; 284: 1263-70. Jonga i-abstract.
  96. ICharland SL, iMalone DC. Ukuxelwa kwangaphambili kokuncitshiswa kwengozi yomsitho we-cardiovascular from lipid changes ehambelana nonyango olunamandla lwe-dyslipidemia. I-Curr Med Res Opin. Ngo-2010; 26: 365-75. Jonga i-abstract.
  97. IGoldberg AC. Uhlalutyo lweemeta kwizifundo ezilawulwa ngokungahleliwe kwiziphumo zokukhululwa kwe-niacin kwabasetyhini. NdinguJ Cardiol. Ngo-2004; 94: 121-4. Jonga i-abstract.
  98. Maes BD, Hiele MI, Geypens BJ, okqhubekayo. Ukumodareyitha kwe-Pharmacological ye-gastric yokukhupha inqanaba lezinto eziqinileyo njengoko kulinganiswa yikhabhoni ebhalwe i-octanoic acid test test: impembelelo ye-erythromycin kunye nepropantheline. Isisu 1994; 35: 333-7. Jonga i-abstract.
  99. Isiteyitimenti se-FDA kuvavanyo lwe-AIM-HIGH. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm256841.htm. (Kufumaneka nge-3 Juni 2011).
  100. Iindaba ze-NIH. I-NIH iyekisa uvavanyo lweklinikhi kunyango lwe-cholesterol. Ngomhla we-26 kuMeyi 2011.http://www.nih.gov/news/health/may2011/nhlbi-26.htm. (Kufumaneka nge-3 Juni 2011).
  101. Uxwebhu lweenkcukacha ze-PL, i-Niacin Plus Statin yokuNciphisa umngcipheko we-Cardiovascular Risk: Isifundo se-AIM-HIGH. Ileta ka-Pharmacist / Ileta yoMmeli. Julayi 2011.
  102. UKarthikeyan K, Thappa DM. Pellagra kunye nesikhumba. I-Int J Dermatol 2002; 41: 476-81. Jonga i-abstract.
  103. Hendricks WM. I-Pellagra kunye ne-pellagralike dermatoses: i-etiology, ukuxilongwa okwahlukileyo, i-dermatopathology, kunye nonyango. Isemina Dermatol 1991; 10: 282-92. Jonga i-abstract.
  104. IBingham LG, iVerma SB. Irhashalala elabiweyo. (Uvavanyo lokuzivavanya lweAmerican Academy of Dermatology). J Ndiyi-Acad Dermatol 2005; 52: 929-32.
  105. UNahata MC. I-chloramphenicol. Ku: Evans WE, Schentag JJ, Jusko WJ (eds). Ukusetyenziswa kweFarmacokinetics: Imigaqo yokuBekwa kweliso kweziyobisi kunyango. 3rd ed., Vancouver, WA: Ukusetyenziswa kweTherapeutics, Inc., 1992.
  106. UDing RW, uKolbe K, uMerz B, et al. I-Pharmacokinetics yokunxibelelana kwe-acid ye-nicotinic-salicylic acid. KwiKlinikhi ye-Pharmacol Ther 1989; 46: 642-7. Jonga i-abstract.
  107. ILyon VB, iFairley JA. I-pellagra ebangelwa yi-Anticonvulsant. Ndiyi-Acad Dermatol 2002; 46: 597-9. Jonga i-abstract.
  108. UKaur S, uGoraya JS, uThami GP, uKanwar AJ. I-Pellagrous dermatitis ebangelwa yi-phenytoin (unobumba). I-Pediatr Derm 2002; 19: 93. Jonga i-abstract.
  109. UWood B, uRademaker M, u-Oakley A, uWallace J. Pellagra kumfazi osebenzisa amanye amayeza. I-Australas J Dermatol 1998; 39: 42-4. Jonga i-abstract.
  110. I-Bender DA, uRussell-Jones R.Isoniazid-eyenzelwe i-pellagra ngaphandle kokongezwa kwe-vitamin B6 (ileta). ILancet 1979; 2: 1125-6. Jonga i-abstract.
  111. UStevens H, Ostlere L, Begent R, et al. I-Pellagra yesibini ukuya kwi-5-fluorouracil. Br J Dermatol 1993; 128: 578-80. Jonga i-abstract.
  112. Swash M, uRoberts AH. Ukubuyiselwa kwakhona kwe-pellagra-encephalopathy kunye ne-ethionamide kunye ne-cycloserine. Ityhubhu 1972; 53: 132. Jonga i-abstract.
  113. I-Brooks-Hill RW, uBhishophu ME, uVellend H. Ndingu-Rev Ukuphendula ngo-1985; 131: 476. Jonga i-abstract.
  114. I-Bender DA, u-Earl CJ, uLee AJ. Ukupheliswa kweNiacin kwizigulana zeParkinsonia eziphathwe nge-L-dopa, benserazide kunye ne-carbidopa. Iklinikhi yeSci 1979; 56: 89-93. . Jonga i-abstract.
  115. I-Ludwig GD, i-White DC. I-Pellagra ibangelwa yi-6-mercaptopurine. Iklinikhi Res 1960; 8: 212.
  116. IStratigos JD, Katsambas A.Pellagra: isifo esisasele sikhona. UBr J Dermatol 1977; 96: 99-106. Jonga i-abstract.
  117. UJarrett P, Duffill M, Oakley A, Smith A. Pellagra, azathioprine kunye nesifo samathumbu esivuthayo. Iiklinikhi Exp Dermatol 1997; 22: 44-5. Jonga i-abstract.
  118. Ulwazi ngemveliso: Niaspan. Kos amayeza. ICranbury, NJ. 2005. Iyafumaneka ku-www.niaspan.com/professional/content/pdfs/productinfo.pdf. (Kufumaneka nge-3 Matshi 2006).
  119. ISchwab RA, iBachhuber BH. I-Delirium kunye ne-lactic acidosis ebangelwa yi-ethanol kunye ne-niacin coingestion. NdinguJ Emerg Med 1991; 9: 363-5. Jonga i-abstract.
  120. Ito MK. Inkqubela phambili ekuqondeni nasekulawuleni i-dyslipidemia: ukusebenzisa unyango olusekwe kwi-niacin. NdinguJ J wezeMpilo-iSyst Pharm 2003; 60 (suppl 2): ​​s15-21. Jonga i-abstract.
  121. Igwele P, Witztum JL. I-Lovastatin, i-nicotinic acid kunye ne-rhabdomyolysis (ileta). UAnn Int Med 1988; 109: 597-8. Jonga i-abstract.
  122. I-Rockwell KA. Unxibelelwano olunokubakho phakathi kwe-niacin kunye ne-transdermal nicotine (unobumba). UAnn Pharmacother 1993; 27: 1283-4. Jonga i-abstract.
  123. UGillman MA, uSandyk R.Nicotinic acid defence ebangelwa yi-sodium valproate (ileta). S Afr Med J 1984; 65: 986 (PubMed) (Umnqamlezo) Jonga i-abstract.
  124. Utata CM. I-Niacinamide kunye ne-acanthosis nigricans (ileta). IArch Dermatol 1984; 120: 1281. Jonga i-abstract.
  125. UMorris MC, uEvans DA, uBianias JL, et al. I-niacin yokutya kunye nomngcipheko wesigulo isifo se-Alzheimer kunye nokwehla kwengqondo. J Neurolurosuroski yengqondo 2004; 75: 1093-99. Jonga i-abstract.
  126. UMcKenney J. Iimbono ezintsha ngokusetyenziswa kwe-niacin kunyango lweengxaki ze-lipid. IArch Intern Med 2004; 164: 697-705. Jonga i-abstract.
  127. Ukuphakamisa i-HDL kunye neNiacin Sebenzisa. Ileta ka-Pharmacist / I-Prescriber's Letter 2004; 20: 200504.
  128. IHoskin PJ, iStratford MR, iSaunders MI, okqhubekayo. Ulawulo lwe-nicotinamide ngexesha letshathi: i-pharmacokinetics, ukunyuka kwedosi, kunye netyhefu yeklinikhi. I-Int J Radiat Oncol Biol Phys 1995; 32: 1111-9. Jonga i-abstract.
  129. UMiralbell R, uMornex F, uGreiner R, et al. Ukukhawulezisa i-radiotherapy, i-carbogen, kunye ne-nicotinamide kwi-glioblastoma multiforme: ingxelo yoMbutho waseYurophu woPhando kunye noNyango lovavanyo lweCancer 22933. J Clin Oncol 1999; 17: 3143-9. Jonga i-abstract.
  130. Anon. I-Niacinamide Monograph. U-Alt Med ngo-2002; 7: 525-9. Jonga i-abstract.
  131. ISchwartz ML. I-hyperglycemia eguqulweyo enamandla njengesiphumo sonyango lwe-niacin. IArch Int Med 1993; 153: 2050-2. Jonga i-abstract.
  132. IKahn SE, iindevu JC, iSchwartz MW, et al. Ukonyusa amandla e-B-cell secretory njengesixhobo se-islet adaptation to nicotinic acid-indased insulin insulin. Iswekile 1989; 38: 562-8. Jonga i-abstract.
  133. Umkhangeli JI, uCalvert RJ, uHathcock JN. Ityhefu ye-Hepatic yamalungiselelo angaguqukiyo kunye nokukhululwa kwexesha le-niacin. NdinguJ Med 1992; 92: 77-81. Jonga i-abstract.
  134. Ikhiwane HL, Ikhiwane J, uSouney PF, et al. I-Nicotinic acid: uphononongo lokusetyenziswa kwayo kweklinikhi kunyango lweengxaki zeepidid. I-Pharmacotherapy ngo-1988; 8: 287-94. Jonga i-abstract.
  135. Iibhayi HE, iDujovne CA. Ukudibana kweziyobisi neziyobisi eziguqula lipid. Iziyobisi Saf 1998; 19: 355-71. Jonga i-abstract.
  136. IVannucchi H, iMoreno FS. Ukudibana kwe-niacin kunye ne-zinc metabolism kwizigulana ezine-pellagra enxilisayo. NdinguJ J Clin Nutriti 1989; 50: 364-9. Jonga i-abstract.
  137. I-Urberg M, iZemel MB. Ubungqina bokusebenzisana phakathi kwe-chromium kunye ne-nicotinic acid kulawulo lokunyamezelana kweswekile kubantu abadala. Imetabolism 1987; 36: 896-9. Jonga i-abstract.
  138. UCheung MC, uZhao XQ, uChait A, et al. Unyango lwe-antioxidant lubhloka impendulo ye-HDL kunyango lwe-simvastatin-niacin kwizigulana ezinesifo semithambo kunye ne-HDL esezantsi. IArterioscler Thromb Vasc Biol 2001; 21: 1320-6. Jonga i-abstract.
  139. UChesney CM, uElam MB, uHerd JA, et al. Iziphumo ze-niacin, warfarin, kunye ne-antioxidant yonyango kwiiparitha ze-coagulation kwizigulana ezinesifo se-arterial isifo kwi-Arterial Disease Multiple Intervention Trial (ADMIT). Intliziyo yam J 2000; 140: 631-6 .. Jonga okungafakwanga.
  140. U-Wink J, uGiacoppe G, uKing J. Iziphumo ze-naicin ephantsi kakhulu kwi-lipoprotein ephezulu kwizigulana ezinyangwa ixesha elide. Intliziyo yam J 2002; 143: 514-8 .. Jonga okungafakwanga.
  141. I-Wolfe ML, iVartanian SF, iRoss JL, et al. Ukhuseleko kunye nokusebenza kweNiaspan xa kongezwe ngokulandelelana kwi-statin kunyango lwe-dyslipidemia. NdinguJ Cardiol 2001; 87: 476-9, A7 .. Jonga i-abstract.
  142. UBrown BG, uZhao XQ, uChait A, et al. I-Simvastatin kunye ne-niacin, iivithamini ze-antioxidant, okanye indibaniselwano yokuthintela isifo se-coronary. N Engl J Med 2001; 345: 1583-93. Jonga i-abstract.
  143. Cumming RG, Mitchell P, Smith W.Ukutya kunye ne-cataract: iBlue Mountains Eye Study. Ophthalmology 2000; 10: 450-6. Jonga i-abstract.
  144. UKuroki F, uIida M, uTominaga M, et al. Ubuninzi bevithamini kwisifo sikaCrohn. Ukulungelelaniswa nomsebenzi wesifo. Ukumba iDis Dis 1993; 38: 1614-8. Jonga i-abstract.
  145. Ukutya kunye neBhodi yeZondlo, iZiko lezeMpilo. Ukufakwa kwereferensi yokutya kwi-Thiamin, i-Riboflavin, i-Niacin, i-Vitamin B6, i-Folate, i-Vitamin B12, i-Pantothenic Acid, i-Biotin kunye ne-Choline. IWashington, DC: ICandelo leSizwe lezeMfundo, 2000. Iyafumaneka kwi: http://books.nap.edu/books/0309065542/html/.
  146. Umbutho weAmerican Dietetic Association. Ifumaneka kwi: www.eatright.org/adap1097.html (Ifumaneka nge-16 kaJulayi 1999).
  147. ILal SM, uHewett JE, uPetroski GF, et al. Iziphumo ze-nicotinic acid kunye ne-lovastatin kwizigulana zokufakelwa kwezintso: ulingo olunokubakho, olungenamkhethe, olunelebheli evulekileyo enelebhile. NdinguJ Kidney Dis 1995; 25: 616-22. Jonga i-abstract.
  148. UGuyton JR, uGoldberg AC, uKreisberg RA, et al. Ukusebenza kwedosi yobusuku ngabunye yokukhutshwa kwe-niacin yodwa kunye nokudibanisa i-hypercholesterolemia. NdinguJ Cardiol 1998; 82: 737-43. Jonga i-abstract.
  149. IVega GL, iGrundy SM. Iimpendulo zeLipoprotein kunyango nge-lovastatin, gemfibrozil, kunye ne-nicotinic acid kwizigulana ze-normolipidemic ezine-hypoalphalipoproteinemia. IArch Intern Med 1994; 154: 73-82. Jonga i-abstract.
  150. I-Vacek JL, i-Dittmeier G, i-Chiarelli T, okqhubekayo. Thelekisa i-lovastatin (20 mg) kunye ne-nicotinic acid (1.2 g) kunye neziyobisi zodwa kuhlobo lwe-II hyperlipoproteinemia. NdinguJ Cardiol 1995; 76: 182-4. Jonga i-abstract.
  151. Illingworth DR, Stein EA, Mitchel YB, et al. Iziphumo zokuthelekisa i-lovastatin kunye ne-niacin kwi-hypercholesterolemia ephambili. Ityala elinokubakho. IArch Intern Med 1994; 154: 1586-95. Jonga i-abstract.
  152. I-Pozzilli P, i-Browne PD, i-Kolb H. Meta-uhlalutyo lonyango lwe-nicotinamide kwizigulana ezine-IDDM yakutshanje. Abavavanyi beNicotinamide. Unonophelo lweSwekile 1996; 19: 1357-63. Jonga i-abstract.
  153. UJohansson JO, uEgberg N, uAsplund-Carlson A, uCarlson LA. Unyango lweNicotinic acid lususa i-fibrinolytic balance ngokulungileyo kwaye inciphise i-plasma fibrinogen kumadoda e-hypertriglyceridaemic. J Cardiovasc Umngcipheko 1997; 4: 165-71. Jonga i-abstract.
  154. URabbani GH, uButler T, uBardhan PK, u-Islam A.Ukuncitshiswa kokulahleka kolwelo kwikholera yi-nicotinic acid: ityala elilawulwa ngokungahleliwe. ILancet 1983; 2: 1439-42. Jonga i-abstract.
  155. Inkqubo yeSizwe yeMfundo yeCholesterol. Ukuncipha kweCholesterol kwisigulana esineCoronary Heart Disease. 1997. Iyafumaneka kwi: http://www.vidyya.com/pdfs/1225cholesterol.pdf. (Kufumaneka ngo-26 Meyi 2016).
  156. UDarvay A, uBasarab T, uMcGregor JM, uRussell-Jones R.Isoniazid wakhupha i-pellagra ngaphandle kokongezwa kwepyridoxine. Iiklinikhi Exp Dermatol 1999; 24: 167-9. Jonga i-abstract.
  157. Ishii N, Nishihara Y.Pellagra encephalopathy phakathi kwezigulana ezinesifo: ubudlelwane bayo kunyango lwe-isoniazid. J Neurolurosuroski yengqondo 1985; 48: 628-34. Jonga i-abstract.
  158. Umbutho waseMelika wezeMpilo kwiNkqubo yezeMpilo. INgxelo yoBume boNyango lwe-ASHP ngokusetyenziswa okukhuselekileyo kwe-niacin kulawulo lwe-dyslipidemias. NdinguJ J Health Syst Pharm 1997; 54: 2815-9. Jonga i-abstract.
  159. Leighton RF, Gordon NF, GS encinci, et al. Intlungu yamazinyo kunye ne-gingival njengeziphumo ebezingalindelekanga zonyango lwe-niacin. Isifuba 1998; 114: 1472-4. Jonga i-abstract.
  160. UGarg A, uGrundy SM. I-Nicotinic acid njengonyango lwe-dyslipidemia kwisifo seswekile esingaxhomekekanga kwi-insulin. IJAMA 1990; 264: 723-6. Jonga i-abstract.
  161. Ikhonkco JR III. Uphuhliso olutsha ekusetyenzisweni kwe-niacin kunyango lwe-hyperlipidemia: ukujonga okutsha ekusebenziseni ichiza elidala. ICoron Artery Dis 1996; 7: 321-6. Jonga i-abstract.
  162. I-Knopp RH. Iiprofayili zeklinikhi zecala ngokuchaseneyo nokukhululwa okuzinzileyo kwe-niacin (i-Niaspan) kunye nesiseko se-physiologic ye-dosing yasebusuku. NdinguJ Cardiol 1998; 82: 24U-28U; ingxoxo 39U-41U. Jonga i-abstract.
  163. IKnopp RH, iAlagona P, uDavidson M, et al. Ukusebenza ngokulinganayo kwefom ye-niacin (Niaspan) enikwe kube kanye-ngobusuku ngokuchasene ne-niacin ecacileyo kulawulo lwe-hyperlipidemia. Imetabolism 1998; 47: 1097-104. Jonga i-abstract.
  164. UMcKenney JM, Proctor JD, Harris S, Chinchili VM. Thelekisa ukusebenza ngokukuko kunye nefuthe elinetyhefu ye-niacin ekhutshiweyo ekhutshwa kwangoko kwizigulana ze-hypercholesterolemic. IJAMA 1994; 271: 672-7. Jonga i-abstract.
  165. Grey DR, Morgan T, Chretien SD, Kashyap ML. Ukusebenza kunye nokhuseleko lwe-niacin ekhutshwayo elawulwayo kumagqala e-dyslipoproteinemic. UAnn Intern Med 1994; 121: 252-8. Jonga i-abstract.
  166. ICapuzzi DM, uGuyton JR, uMorgan JM, et al. Ukusebenza kunye nokukhuseleka kwe-niacin eyandisiweyo (Niaspan): isifundo sexesha elide. NdinguJ Cardiol 1998; 82: 74-81; idiski. I-85U-6U. Jonga i-abstract.
  167. IJungnickel PW, iMaloley PA, iVander Tuin EL, et al. Iziphumo zeerejimeni zangaphambi kokunyanga ngaphambi kwexesha kwi-niacin-induction reaction. J Uhlobo lwangaphakathi lweMed 1997; 12: 591-6. Jonga i-abstract.
  168. IWhelan AM, Ixabiso SO, iFowler SF, iHainer BL. Iziphumo zeasprini kwi-niacin-indased reaction cutaneous. J Fam Ukuziqhelanisa 1992; 34: 165-8. Jonga i-abstract.
  169. IGibbons LW, uGonzalez V, uGordon N, uGrundy S.Ukuxhaphaka kweziphumo ebezingalindelekanga ezinokukhutshwa rhoqo kwe-nicotinic acid. NdinguJ Med 1995; 99: 378-85. Jonga i-abstract.
  170. Ipaki YK, Sempos CT, Barton CN, et al. Ukusebenza kokuqiniswa kokutya eMelika: imeko yepellagra. NdinguJ J wezeMpilo kaRhulumente 2000; 90: 727-38. Jonga i-abstract.
  171. UZhao XQ, uBrown BG, uHillger L, et al. Iziphumo zonyango olunamandla lokunciphisa i-lipid kwimithambo ye-coronary ye-asymptomatic masomo ene-apolipoprotein ephezulu B. Ukujikeleza ngo-1993; 88: 2744-53. Jonga i-abstract.
  172. ICannner PL, iBergge KG, uWenger NK, et al. Ishumi elinesihlanu lokufa kwabantu kwizigulana zeCoronary Drug Project: isibonelelo sexesha elide kunye ne-niacin. NdinguColl Cardiol 1986; 8: 1245-55. Jonga i-abstract.
  173. UGuyton JR, uBlazing MA, uHagar J, et al. Ukukhululwa kwe-niacin vs gemfibrozil eyandisiweyo kunyango lwamanqanaba asezantsi e-lipoprotein cholesterol ephezulu. Iqela leNiaspan-Gemfibrozil. IArch Intern Med 2000; 160: 1177-84. Jonga i-abstract.
  174. UZema MJ. I-Gemfibrozil, i-nicotinic acid kunye nonyango oludibeneyo kwizigulana ezine-hypoalphalipoproteinemia ekhethiweyo: ileyibhile evulekileyo, evulekileyo, yokufunda crossover. NdinguColl Cardiol 2000; 35: 640-6. Jonga i-abstract.
  175. IKnodel LC, uTalbert RL. Iziphumo ezibi zeziyobisi ze-hypolipidaemic. IMed Toxicol 1987; 2: 10-32. Jonga i-abstract.
  176. IiYates AA, iSchlicker SA, iSuitor CW. Ukungeniswa kwereferensi yezidlo J Nditya i-Assoc 1998; 98: 699-706. Jonga i-abstract.
  177. Shils ME, Olson JA, Shike M, Ross AC, ii-eds. Isondlo sangoku kwezempilo nakwizifo. Umhla we-9. IBaltimore, MD: UWilliams kunye noWilkins, ngo-1999.
  178. Reimund E.Ukuthothisa ubuthongo obubangelwa kukulala: ukuxhaswa ngakumbi kwe-nicotinic acid yokuphelelwa kukulala. Iingcinga ngo-1991; 36: 371-3. Jonga i-abstract.
  179. UIoannides-Demos LL, uChristophidis N, et al. Ukunyanzelwa kokunxibelelana kweklinikhi phakathi kwejusi yamagilebhisi kunye necyclosporine kunye nokugxila kwimetabolite kwizigulana ezinezifo ezizimele. J Rheumatol 1997; 24: 49-54. Jonga i-abstract.
  180. UHardman JG, uLimbird LL, uMolinoff PB, ii-eds. UGoodman noGillman's Isiseko seFarmacological of Therapeutics, umhla we-9. ENew York, NY: McGraw-Hill, 1996.
  181. UGarg R, uMalinow MR, uPettinger M, et al. Unyango lwe-Niacin lwonyusa amanqanaba e-plasma homocysteine. Ndiyintliziyo J 1999; 138: 1082-7. Jonga i-abstract.
  182. UGruenwald J, uBrendler T, uJaenicke C. PDR wamaYeza eHerbal. Umhla woku-1. IMontvale, NJ: Inkampani yezoQoqosho kwezonyango, Inc., 1998.
  183. UMcEvoy GK, ed. Ulwazi lwe-AHFS yeziyobisi. I-Bethesda, MD: Umbutho waseMelika we-Health-System Pharmacists, 1998.
Ukuhlaziywa okokugqibela-10/16/2020

Iimpapasho Ezintsha

I-5 yeeLogo zikaGoogle ezikhuthazwe nguKomelela Sithanda ukuBona
Indlela Yokuphila

I-5 yeeLogo zikaGoogle ezikhuthazwe nguKomelela Sithanda ukuBona

it alele umnxeba, kodwa iyathanda xa uGoogle et hint ha ilogo yakhe ayenze into emnandi kunye noyilo. Namhlanje, ilogo kaGoogle iboni a i elfowuni ka-Alexander Calder ehambayo ukubhiyozela oko bekuya...
Izinto ezi-5 ekumele zenziwe ngale mpelaveki yoSuku lomSebenzi phambi kokuphela kwehlobo
Indlela Yokuphila

Izinto ezi-5 ekumele zenziwe ngale mpelaveki yoSuku lomSebenzi phambi kokuphela kwehlobo

Impelaveki yo uku lom ebenzi inokuba ele ikufut hane nekona, kodwa u eneeveki ezimbini ezigcweleyo ukonwabela yonke ihlobo. Ke, ngaphambi kokuba uqale ukunxiba iijean kwaye u-odole ii-latte ezinamatha...